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Leprosy is a chronic bacterial infection caused by Mycobacterium leprae, which may lead to
physical disability, stigma, and discrimination. The chronicity of the disease and disabilities
are the prime contributors to the disease burden of leprosy. The current figures of the dis-
ease burden in the 2017 global burden of disease study, however, are considered to be
under-estimated. In this study, we aimed to systematically review the literature and perform
individual patient data meta-analysis to estimate new disability weights for leprosy, using
Health-Related Quality of Life (HRQOL) data.
Methodology/principal findings
The search strategy included all major databases with no restriction on language, setting,
study design, or year of publication. Studies on human populations that have been affected
by leprosy and recorded the HRQOL with the Short form tool, were included. A consortium
was formed with authors who could share the anonymous individual-level data of their
study. Mean disability weight estimates, sorted by the grade of leprosy disability as defined
by WHO, were estimated for individual participant data and pooled using multivariate ran-
dom-effects meta-analysis. Eight out of 14 studies from the review were included in the
meta-analysis due to the availability of individual-level data (667 individuals). The overall
estimated disability weight for grade 2 disability was 0.26 (95%CI: 0.18–0.34). For grade 1
disability the estimated weight was 0.19 (95%CI: 0.13–0.26) and for grade 0 disability it was
0.13 (95%CI: 0.06–0.19). The revised disability weight for grade 2 leprosy disability is four
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times higher than the published GBD 2017 weights for leprosy and the grade 1 disability
weight is nearly twenty times higher.
Conclusions/significance
The global burden of leprosy is grossly underestimated. Revision of the current disability
weights and inclusion of disability caused in individuals with grade 0 leprosy disability will
contribute towards a more precise estimation of the global burden of leprosy.
Author summary
Leprosy is a chronic, disabling disease that causes various kinds of disability in the affected
person. This includes physical impairment, activity limitation, and participation restric-
tion. However, the published global burden of disease estimates for leprosy is considered
to be a gross under-estimation. Disability weights form an integral component in the cal-
culation of the burden estimates. But the methodology for calculation of the weights
focuses only on physical impairment and lacks the perspective of the patient. In this study,
we systematically reviewed the literature and performed an individual patient data meta-
analysis for revising the disability weights for leprosy using domain scores from health-
related quality of life instruments. The domains of these instruments cover all aspects of
disability from a patient’s perspective. We found that the revised weights were consider-
ably higher than the current weights, and were more reflective of the actual disability
caused by leprosy. We also found that for individuals without any severe disability due to
leprosy (grade 0), they still experience comparable suffering. Revision of the current dis-
ability weights and inclusion of the disability caused in grade 0 individuals will contribute
towards better estimation of the global burden of leprosy.
Introduction
Leprosy is a chronic bacterial infection caused by Mycobacterium leprae, which may lead to
physical disability, stigma, and discrimination. Every year, around 200,000 new leprosy cases
are detected worldwide and 12,800 persons are diagnosed with advanced disfigurement
(referred to as leprosy grade 2 disability), which is irreversible in nature [1]. Leprosy is often
misunderstood to be eliminated or carry no significant disease burden because most cases
have limited physical impairment. In reality, the burden of leprosy is beyond physical
impairment and encompasses the mental and social wellbeing of affected persons [2, 3]. The
World Health Organization (WHO) defines ‘disability’ as an umbrella term that covers physi-
cal impairment, activity limitation, and participation restriction [4]. In leprosy, an alternative
definition of disability has traditionally been used; grades 0, 1, and 2 disability [5].
Disease burden can be expressed by Disability Adjusted Life Years (DALYs), a measure that
was introduced in 1990 and gained significance with the Global Burden of Disease(GBD) 1996
study [6]. The aim was to holistically quantify disease burden by accounting for morbidity and
mortality. DALYs are commonly used to compare the disease burden and set priorities for
health policy [7]. The calculation of DALY involves the addition of the Years of Life Lost
(YLL) to Years Lived with Disability (YLD) [8]. An important component of the YLD is the
pre-calculated disability weight, which has a value ranging from 0 (a state of full health)
through 1 (a state equal to death) [9, 10].
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It was argued that GBD’s quantification of disability weights was based only on the prefer-
ences of experts [11, 12]. However, GBD later updated the methodology by including the pref-
erences of general populations in their surveys [8, 9]. It has also been argued that the health
state descriptions to calculate disability weights are not accurate for some diseases [11], includ-
ing leprosy. The descriptions do not always capture all the aspects of disability, such as activity
limitation and participation restriction, and sometimes focus only on physical impairment
[12]. Therefore the disability weights for leprosy grades 1 and 2 are suspected to be under-esti-
mated for leprosy. Furthermore, no disability weights are assigned in the current GBD study
to leprosy patients without any form of physical disability (grade 0), who still may experience
poor mental health. The suspected under-estimation of disability weights is flagged by experts
[13, 14], but no empirical evidence is available to indicate the magnitude. Improving the health
state description will have a direct impact on the global estimation of leprosy burden.
The disability weights can be revised by using Health-Related Quality Of Life (HRQOL)
instruments, which cover all three aspects of disability (physical impairment, activity limita-
tion, and participation restriction) equally [15]. HRQOL data can be obtained as (a) Non-Pref-
erence based measures, and (b) Preference-based measures [16]. Non-preference based
measures describe health states as one or more domains, while preference-based measures
assign a ’weight/index value’ to the health state from an individual or population, to yield a
summary score. For leprosy, the former is the most commonly used method to measure
HRQOL. The HRQOL questionnaires can measure the health state from the perspective of the
patient and cover all the three aspects of disability.
There is an urgent need to revise the leprosy disability weights for priority setting in health
policy, resource allocation, and advocacy. Currently, leprosy is neglected among the Neglected
Tropical Diseases (NTD) group and prioritized as the third-least burdened disease [8]. The
aim of our study is to compare the current GBD leprosy disability weights with new weights
derived using HRQOL measures of leprosy patients. The objectives are: 1) to identify studies
that measured HRQOL of leprosy patients; and 2) to assess leprosy disability weights based on
the existing HRQOL data. We expect that the revised disability weight will be useful to correct
the global leprosy burden. The revised disability weights will also aid to determine the cost-
effectiveness of new interventions for treatment in leprosy, which are currently imperative [7].
Methods
This systematic review and meta-analysis was conducted and reported following the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [17] (S1
Table). First, we searched the International Prospective Register of Systematic Reviews data-
base (PROSPERO) for any similar ongoing or published literature reviews. We then developed
a review protocol and registered it with PROSPERO (CRD42019146494).
Data sources and search strategy
The search strategy (S1 Appendix) was created in collaboration with an information specialist
at the Erasmus MC library, with input from the research group. We searched articles on vari-
ous databases and scrutinized references of the relevant studies. Additionally, we received
assistance from the international knowledge center for information resources on leprosy
(INFOLEP) [18] in searching for grey literature, such as conference proceedings and inaccessi-
ble data. The databases were searched with no restriction on language, year of publication,
study design, or setting. We adequately translated non-English publications using online trans-
lation tools.
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Study selection
We performed the screening process as a limited dual review. Title and abstracts were first
screened by two independent reviewers (SLNC and AT) on a random sample (n = 303) of the
study abstracts with clearly defined eligibility criteria (S1 Appendix). An inter-rater agreement
of 95% was observed (Kappa = 0.82), which is deemed to be strong [19]. The discrepancies
that existed between the reviewers at this stage were resolved through discussion. Based on the
discussions at this stage, the screening of the remaining titles and abstracts was adopted by the
first reviewer (SLNC). The next stages of screening of the full texts of the selected studies and
data-extraction were also carried out by the first reviewer (SLNC). Microsoft Excel spread-
sheets and EndNote X9.2 were used for data extraction and management, respectively.
Data extraction and meta-analysis
Based on the eligibility criteria, we identified studies that used any version of the SF-36 tool, to
measure HRQOL in leprosy patients. In September 2019, we sent an invitation to the authors
of those studies for joining the Study Consortium. The consortium was set up by including
authors who could share the anonymous individual-level data of their study. Primary out-
comes of interest were the grade of leprosy disability and eight domain scores of the SF-36
tool.
The Short Form (SF)-36 questionnaire contained 36 items that measured eight health
domains: physical functioning, role limitations (physical), bodily pain, general health, vitality,
social functioning, role limitations (emotional), and mental health [20]. Aggregated summary
scores namely the Physical Component Summary (PCS) and the Mental Component Sum-
mary (MCS), was obtained from the eight domains [21]. Data on age, gender, leprosy type (PB
or MB), the grade of disability (Grade 0, 1 or 2), and HRQOL domain scores recorded at base-
line for each individual, were used for the analysis. We also confirmed the version of the SF-36
tool used by the authors and checked the scoring methodology for each study.
We imputed any missing data values for each included study separately, using the Multiple
Imputation by Chained Reactions (MICE) method. The results of the multiple imputation
were investigated using convergence plots (Figs A-D in S2 Appendix). We estimated PCS and
MCS scores from the domains of all individual patients, following an oblique factor analysis
that allowed for correlation of the underlying factors [22]. We also checked for the sensitivity
of the imputation, by re-running the analyses excluding all observations with missing data
values.
We transformed the individual SF-36 PCS and MCS scores into equivalent disability
weights using a mapping function developed from SF-12 scores (a shortened version of SF-
36), by the Institute for Health Metrics and Evaluation (IHME) [23]. The mapping function is
based on a loess regression, which returns a disability weight for each composite score
(Table B in S2 Appendix). For this, we combined the PCS and MCS scores into a summary
score, through simple addition. For a study with multiple imputations, we sorted the estimated
disability weights by disability grades for each imputed dataset. Then we pooled the sorted dis-
ability weights from each imputation following Rubin’s rules [24]. For a study with no imputa-
tion, we estimated the mean disability weights, which were also sorted by disability grades.
For meta-analyses, we applied a two-stage multivariate random-effects model to estimate
overall mean weights for disability grades 0, 1, and 2 from all consortium studies. Furthermore,
we compared the difference between grades 0, 1, and 2 overall disability weights. The inter-
study heterogeneity was presented using the I2 statistic. To visualize the results of the meta-
analyses we generated forest plots for each grade of disability using a univariate random-effects
model. The difference in the estimated weights using the two models were also compared.
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In the end, we compared our results to the current disability weights for leprosy, published
in the 2017 GBD study. We also used the multivariate meta-analysis approach to estimate
overall mean scores for each of the eight SF-36 domains. The meta-analyzed domain scores
were sorted by the grade of disability to test for differences in the overall mean domain scores
between the grades. We performed all statistical analyses using R version 3.5.3.
Results
Literature search
Fig 1 presents the results through the PRISMA flowchart. The literature search yielded 2195
articles. The screening of titles and abstracts resulted in 265 studies that appeared to meet the
selection criteria. Following the screening of full text of the included articles, a total of 13 stud-
ies were included as they recorded and reported HRQOL scores from the SF-36 tool from peo-
ple affected by leprosy. One other study reporting SF-36 scores was included from
supplementary sources and snowballing procedures while searching for studies published until
2019.
Table 1 presents the study characteristics of the fourteen studies that reported the use of the
SF-36 tool. Of these studies, eight were included in further analyses because of the availability
of individual-level data (n = 667 patients). In all the studies the proportion of male participants
was higher than females. Not all studies reported the type of leprosy of the participants
(n = 143) and a few had missing disability grades. No issues were identified on checking the
methodology of scoring of SF-36 domains in the included studies. The number of missing data
points, if present, were also summarized (S2 Appendix).
Meta-analysis
Data from eight studies were included in the final meta-analysis. One of the publications [27]
included two pilot trials, which are represented separately in the analysis. Fig 2 provides an
overview of the overall disability weights for the Grade 2, Grade 1, and Grade 0 disability from
the univariate meta-analysis model, for ease of presentation.
Table 2 shows that the differences in the estimated disability weights between the univariate
and multivariate meta-analysis models are negligible. But we considered the results of the Mul-
tivariate model for reporting in this manuscript because the multivariate model can handle
more variability in the analysis than the univariate model. The disability weight for grade 2
was 0.26 (95%CI: 0.18–0.34). For grade 1 disability the estimated weight was 0.19 (95%CI:
0.13–0.26) and grade 0 estimated weight was 0.13 (95%CI: 0.06–0.19). A sensitivity analysis of
the imputation showed near similar results (Tables C-D in S2 Appendix).
A test for differences in the estimated disability weights between the three grades of leprosy
disability revealed that the weights for grade 1 (0.19) and grade 2 (0.26) were statistically signif-
icantly different from grade 0 (0.12)(Table A in S3 Appendix). However, the grade 1 weight
was not statistically significantly different from the grade 2 weight.
Table 3 shows the comparison of the estimated disability weights from our multivariate
meta-analysis to current 2017 GBD estimates for leprosy [8]. Table 4 shows the current GBD
health state description and proposed health state descriptions for all the three grades of lep-
rosy disability, which have been rephrased based on our meta-analyzed HRQOL results.
Fig 3 shows a spider plot of the meta-analyzed domain scores, for each of the disability
grades from the multi-variate random-effects model (Table B in S3 Appendix). The Mental
Health (MH) mean domain scores were similar in all the three disability grades. While the
grade 2 mental health score was not statistically significantly different from grade 0 scores,
only marginal statistical significance was observed between the mean mental health scores of
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grade 0 and grade 1 (Table C in S3 Appendix). For grades 1 and 2, the General Health (GH)
and Role limitations due to physical deformity (RP) were the least scored domains with mean
scores of 43.70 [95%CI:35–52] and 37.74 [95%CI: 29–47], respectively. The Bodily pain (BP)
domain was the second-least scored domain in both grade 1–46.5 [95%CI: 35–58] and grade
2–42.18 [95%CI:31–53] disabilities. However, for grade 0 disability the General Health (GH)-
52.28 [95%CI: 44–61] and Bodily Pain (BP) = 54.4 [95%CI: 42–67] were the two least scoring
domains.
Discussion
Our study derived new estimates of leprosy disability weights based on SF-36 HRQOL scores.
The overall estimated disability weight for grade 2 disability was 0.26 (95%CI: 0.18–0.34). For
grade 1 disability the estimated weight was 0.19 (95%CI: 0.13–0.26) and for grade 0 disability it
was 0.13 (95%CI: 0.06–0.19). The revised disability weight for grade 2 leprosy disability is four
Fig 1. PRISMA Flowchart. n- Number of citations, QOL- Quality of Life, IPD- Individual participant data.
https://doi.org/10.1371/journal.pntd.0009209.g001
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times higher than the published GBD 2017 weights for leprosy and the grade 1 the disability
weight is nearly twenty times higher.
In our study, we determine the under-estimation of the leprosy burden based on empirical
evidence. Our meta-analysis is based on data from different time points and geographical set-
tings, hence the external validity is high. Furthermore, the use of individual-level patient data
increased the reliability of the estimates. The mapping function used for transforming
HRQOL data into disability weights is in line with IHME proposed methods, therefore the
acceptance of results can be expected to be high. Finally, the proposed lay descriptions for the
disability grades of leprosy were rephrased based on the findings of a reliable and multidimen-
sional patient-reported outcome measure.
As a limitation, we could not include individual data from six of the fourteen identified
studies, due to the non-availability of individual data. However, we tried to utilize the HRQOL
summary estimates from fourteen studies to understand the overall influence of HRQOL on
aspects of disability, i.e., physical impairment, participation restriction, and activity limitation.
The derived weights were not corrected for comorbidity, because no data was recorded for
comorbidity in most studies. Though, the SF-36 has been designed to provide only a general
measure of mental health for most conditions, the use of more sensitive instruments for mea-
suring patient experiences like anxiety and depression [39] would have contributed to more
accurate estimates of disability burden in leprosy. Quality appraisal of the included studies was
not conducted, because the main focus of the research question was on estimating new weights
from the individual participant data that were observed at baseline. Although the studies were
from different geographical settings, no study was identified and included from India, which
yields the highest number of new cases, globally.
The differences in our disability weights compared to GBD 2017 weights are due to the
inclusion of mental health status, activity limitation, and pain, among other effects of leprosy
as perceived by the patients. Mental health is one of the lowest scoring domains across all three
Table 1. Study Characteristic.
First Author, Year HRQL instrument Country N % of Females (number) Mean Age (Range) Type of Leprosy
�Demir, et al., 2014 [25] SF-36 V1 Turkey 35 31 (11) 75 (41–96) PB- 0; MB-35
�Watanabe, H., 2013 [26] SF-36 V2 Vietnam 143 40 (57) 61 (12–89) Not recorded







�Lambert, et al., 2016 [28] SF-36 V1 Ethiopia 73 21 (15) 34 (18–60) PB-0; MB-73
�do Prado, et al., 2011 [29] SF-36 V1 Brazil 97 32 (31) 51 (20–89) PB-13; MB-84
�Guimenes, et al., 2019 [30] SF-36 V1 Brazil 104 44 (46) 46 (21–80) PB-20; MB-84
�Bowers, et al., 2017 [31] RAND-36 Bangladesh 75 20 (15) 36 (15–62) PB-3; MB-72
�Lustosa, et al., 2011 [32] SF-36 V1 Brazil 107 37 (40) 45 (15–86) PB-50, MB-57
Diaz, et al., 2008 [33] SF-36 V1 Brazil 12 58 (7) 50 Unavailable
Sales, et al., 2017 [34] SF-36 V1 Brazil 59 22 (13) 46 (19–83) BB-2; BL-16; LL-41
Wan, et al..2017 [35] RAND-36 Ecuador 19 37 (7) 56 Unavailable
Araujo, et al., 2016 [36] SF-36 V1 Brazil 59 46 (27) 46 PB-11; MB-46
Borges-De-Oliveira, et al., 2015 [37] SF-36 V1 Brazil 126 44 (55) 42 (18–79) PB-42; MB-84
Bottene, et al., 2012 [38] SF-36 V1 Brazil 49 67 (33) 56 PB-49; MB-0
Study population: N- Sample size, F- Females, PB- Paucibacillary, MB- Multibacillary, RAND- Research and Development, SF- Short Form. The RAND-36 is a publicly
available version of the SF-36 that uses a different scoring method.
� Included for meta-analysis.
# Contains two pilot trials that are analyzed as separate datasets.
https://doi.org/10.1371/journal.pntd.0009209.t001
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Fig 2. Forest plots for the three grades of leprosy disability. N- Number of participants; Plots obtained with the univariate random-effects model.
https://doi.org/10.1371/journal.pntd.0009209.g002
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grades of leprosy disability. This domain captures how the person feels, including their degree
of nervousness and anxiety. Our results are consistent with studies that showed poor mental
health in leprosy irrespective of disability. Poor mental health is associated with the high
stigma and discrimination experienced by people affected by leprosy for a long time even after
the successful completion of antimicrobial multidrug treatment [32, 40, 41]. The role limita-
tions-physical was the least scoring domain among leprosy patients with grade 2 disability,
indicating that they face problems in performing regular daily activities as a result of their
physical health. A cross-sectional survey by Van Brakel et al. (2012) also described a high pro-
portion of persons with leprosy reporting activity limitations [2]. The same study also showed
that limitation in activities increased the risk of social participation restriction and societal dis-
crimination of persons with leprosy. Our results also showed that patients across all three
grades of leprosy disability (including grade 0) reported that pain interfered considerably with
their normal work. A review by Thakur et al. (2015) also showed that both acute pain associ-
ated with leprosy reactions and occurring as intermittent episodes and chronic (neuropathic)
pain were common presenting symptoms among leprosy patients [42]. The physical role limi-
tations and bodily pain may have largely contributed to the low scores of the general health
domain, for all the grades of leprosy disability.
If the mental health, activity limitation, and bodily pain will be captured sensitively through
an appropriate health state description as proposed in our study, then the weights and global
burden of leprosy will increase multifold [43]. Modification of disability weights for other
NTDs, through the incorporation of the psychological impact of disease has been made in pre-
vious GBD studies [44]. Overall, the patient perspective contributed most to the difference in
the disability weights. Our revised grade 2 weights are comparable with the GBD 2017 weights
of idiopathic-less severe epilepsy (S2 Table). In addition to a general modelling strategy, the
GBD study uses different methods for each disease to estimate its global burden. Currently,
the leprosy burden is ranked third-last among thirteen NTDs [8], but after considering the
revised weights, leprosy is expected to be ranked in the middle order of NTDs.
The early versions of the GBD studies assigned an average disability weight of 0.152 to
grades 1 and 2 [45]. The GBD revised its leprosy weights in 2013 [9] and used the same weights
in the 2017 burden estimation [8]. The applied methodology was paired comparison of data
Table 2. Meta-Analyses Model Results.
Grade Disability Weight Estimate Standard Error 95% Confidence Interval
Uni Multi Uni Multi Uni Multi
lower upper lower upper
0 0.13 0.12 0.03 0.03 0.06 0.20 0.06 0.19
1 0.19 0.19 0.03 0.03 0.13 0.25 0.13 0.26
2 0.26 0.26 0.04 0.04 0.19 0.34 0.18 0.34
Uni- Two-stage univariate random effects model, Multi- Two-stage random effects multivariate model
https://doi.org/10.1371/journal.pntd.0009209.t002
Table 3. Comparison of the revised and GBD 2017 leprosy disability weights.
Disability Grade due to Leprosy Revised Disability Weights GBD 2017 Disability Weights for leprosy
Grade 0 –not reported in GBD studies 0.12 [0.06–0.19] NR
Grade 1 0.19 [0.13–0.26] 0.01 [0.01–0.02]
Grade 2 0.26 [0.18–0.34] 0.07 [0.04–0.10]
NR- Not reported, GBD- Global burden of Disease
https://doi.org/10.1371/journal.pntd.0009209.t003
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collected from the general population, whereas we analyzed SF-36 HRQOL data of individual
patients. The difference in methodology is one of the reasons for a drastic difference in the
weights. The advantage of HRQOL based weights is that they can sufficiently capture disease
burden by covering the patient’s perspective [15]. In several instances, GBD considered
HRQOL methodology to revise the burden estimates of diseases such as Chronic Obstructive
Pulmonary Disease (COPD)and Major Depressive Disorder (MDD) [8].
The revised weights for leprosy disability grade 0 are near similar to grade 1 weights, which
implies that the leprosy patients without any visible disability also experience comparable suf-
fering. The proximity in the weights- grade 0 and 1 is largely due to the similarity in the scores
of the mental components of the SF-36 tool.
We opted to calculate the PCS and MCS composite scores using oblique factor coefficients
[22] over orthogonal factor coefficients [21] because the latter was criticized [46] for its assump-
tion that the two components were independent (uncorrelated). A mapping function was essen-
tial to calculate the disability weights from PCS and MCS scores. Therefore, we selected a
mapping function developed from SF-12 composite scores proposed by IHME. The SF-12 tool
[47] is a shortened version of the more reliable SF-36. The use of the SF-36 composite scores as
a proxy to the SF-12 scores is justified because both scores are highly correlated [20, 47].
Recommendations
We recommend revising the health state descriptions for the two leprosy disability grades
because the current description excludes activity limitation and participation restriction
aspects that are experienced by the patients. The sequelae base of leprosy should be broadened
by including leprosy grade 0 disability patients because its revised weight is close to grade 1.
The GBD used a general health state description to calculate the disability weights, which are
sensitive to this description. We recommend revising the health state description for leprosy
because the current description excludes activity limitation and participation restriction
aspects. Finally, there is a need for SF-36 HRQOL studies from India to be included in the
future revision of the leprosy disability weights.
Conclusion
We conclude that the global burden of leprosy is grossly underestimated. Comparable to the
patients of grade 2 disability, grade 1 and grade 0 patients also experience a similar level of
Table 4. GBD 2017 health state descriptions for leprosy.
Sequela GBD health state description for leprosy Newly proposed health state description
for leprosy
Disfigurement Level 1 due
to leprosy (WHO leprosy
grade 0)
NR Has no visible deformity, but skin lesions
and mild pain, which causes some mental
distress, but no difficulty with daily
activities
Disfigurement Level 2 due
to leprosy (WHO leprosy
grade 1)
Has a slight visible deformity that others
notice, which causes some worry and
discomfort
Has a slight visible deformity, often with
moderate pain, which often causes some
mental distress, and some difficulty with
social and daily activities
Disfigurement Level 3 due
to leprosy (WHO leprosy
grade 2)
Has visible deformity that causes others
to stare and comment. As a result, the
person is worried and has trouble
sleeping and concentrating
Has visible deformity, often with severe
pain, which often causes a lot of mental
distress, and great difficulty with social
and daily activities
NR- Not Reported, WHO- World Health Organization
https://doi.org/10.1371/journal.pntd.0009209.t004
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poor mental health and quality of life. Revision of the current disability weights and inclusion
of disability caused in individuals with grade 0 leprosy disability will contribute towards a
more precise estimation of the global burden of leprosy.
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25. Demir B, Ucak H, Dertlioglu S, Demir Ş, Güler K, Cicek D, et al. Quality of life in lepromatous leprosy
patients. TURKDERM. 2014; 48:146–51.
26. Watanabe H. [Quality of life of leprosy patients’ group in Vietnam]. Nihon Hansenbyo Gakkai Zasshi.
2013; 82(3):83–98. https://doi.org/10.5025/hansen.82.83 PMID: 24579455
PLOS NEGLECTED TROPICAL DISEASES Revised estimates of leprosy disability weights for assessing the global burden of disease
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009209 March 2, 2021 13 / 14
27. Lambert SM, Nigusse SD, Alembo DT, Walker SL, Nicholls PG, Idriss MH, et al. Comparison of Efficacy
and Safety of Ciclosporin to Prednisolone in the Treatment of Erythema Nodosum Leprosum: Two Ran-
domised, Double Blind, Controlled Pilot Studies in Ethiopia. PLoS Negl Trop Dis. 2016; 10(2):
e0004149. https://doi.org/10.1371/journal.pntd.0004149 PMID: 26919207
28. Lambert SM, Alembo DT, Nigusse SD, Yamuah LK, Walker SL, Lockwood DN. A Randomized Con-
trolled Double Blind Trial of Ciclosporin versus Prednisolone in the Management of Leprosy Patients
with New Type 1 Reaction, in Ethiopia. PLoS Negl Trop Dis. 2016; 10(4):e0004502. https://doi.org/10.
1371/journal.pntd.0004502 PMID: 27046330
29. Do Prado GD, Prado RB, Marciano LH, Nardi SM, Cordeiro JA, Monteiro HL. WHO disability grade
does not influence physical activity in Brazilian leprosy patients. Lepr Rev. 2011; 82(3):270–8. PMID:
22125935
30. Guimenes Albuquerque R, Grudtner Buratto G, Hirotsu C, Maeda SM, Floriano MC, Levy Andersen M,
et al. Comparison of quality of life evaluated by SF-36 and DLQI in multibacillary and paucibacillary lep-
rosy patients from Sao Paulo, Brazil. Int J Dermatol. 2019; 58(12):1415–22. https://doi.org/10.1111/ijd.
14489 PMID: 31148144
31. Bowers B, Butlin C, Alam K, Lockwood D, Walker SL. Health-Related Quality of Life amongst people affected
by Erythema Nodosum Leprosum in Bangladesh: a Cross Sectional Study. Leprosy review. 2017;88.
32. Lustosa AA, Nogueira LT, Pedrosa JI, Teles JB, Campelo V. The impact of leprosy on health-related
quality of life. Rev Soc Bras Med Trop. 2011; 44(5):621–6. https://doi.org/10.1590/s0037-
86822011000500019 PMID: 22031079
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37. Borges-de-Oliveira R, Rocha-Leite CI, Araujo-de-Freitas L, Queiroz DA, Machado PRL, Quarantini LC.
Perception of social exclusion, neuropathy, and quality of life among Hansen’s disease patients. The
International Journal of Psychiatry in Medicine. 2015; 49(3):176–86. https://doi.org/10.1177/
0091217415582173 PMID: 25930737
38. Bottene IMC, Reis VMSd. Quality of life of patients with paucibacillary leprosy. Anais Brasileiros de Der-
matologia. 2012; 87:408–11. https://doi.org/10.1590/s0365-05962012000300009 PMID: 22714756
39. Somar P, Waltz MA-O, van Brakel WA-O. The impact of leprosy on the mental wellbeing of leprosy-
affected persons and their family members—a systematic review. (2054–4251 (Print)).
40. Tsutsumi A, Izutsu T, Islam AM, Maksuda AN, Kato H, Wakai S. The quality of life, mental health, and
perceived stigma of leprosy patients in Bangladesh. Soc Sci Med. 2007; 64(12):2443–53. https://doi.
org/10.1016/j.socscimed.2007.02.014 PMID: 17382441
41. Remme JHF, Feenstra P, Lever PR, Medici AC, Morel CM, Noma M, et al. Tropical Diseases Targeted
for Elimination: Chagas Disease, Lymphatic Filariasis, Onchocerciasis, and Leprosy. In: nd, Jamison
DT, Breman JG, Measham AR, Alleyne G, Claeson M, et al., editors. Disease Control Priorities in
Developing Countries. Washington (DC) 2006.
42. Thakur S, Dworkin R, Haroun O, Lockwood D, Rice A. Acute and chronic pain associated with leprosy.
Pain. 2015;156. https://doi.org/10.1097/j.pain.0000000000000178 PMID: 25830927
43. Bailey F, Eaton J, Jidda M, van Brakel WH, Addiss DG, Molyneux DH. Neglected Tropical Diseases
and Mental Health: Progress, Partnerships, and Integration. (1471–5007 (Electronic)).
44. Bailey FA-O, Mondragon-Shem KA-O, Haines LR, Olabi A, Alorfi AA-O, Ruiz-Postigo JA, et al. Cutane-
ous leishmaniasis and co-morbid major depressive disorder: A systematic review with burden esti-
mates. (1935–2735 (Electronic)).
45. Mathers CD, Ezzati M, Lopez AD. Measuring the burden of neglected tropical diseases: the global bur-
den of disease framework. PLoS neglected tropical diseases. 2007; 1(2):e114–e. https://doi.org/10.
1371/journal.pntd.0000114 PMID: 18060077
46. Taft C, Karlsson J, Sullivan M. Do SF-36 Summary Component Scores Accurately Summarize Sub-
scale Scores? Quality of life research: an international journal of quality of life aspects of treatment, care
and rehabilitation. 2001; 10:395–404. https://doi.org/10.1023/a:1012552211996 PMID: 11763202
47. Ware JE, Keller SD, Kosinski M. SF-12: how to score the SF-12 physical and mental health summary
scales 1995.
PLOS NEGLECTED TROPICAL DISEASES Revised estimates of leprosy disability weights for assessing the global burden of disease
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009209 March 2, 2021 14 / 14
